ranpirnase (Pannon)

Pannon is a paritally purified extract of ranpirnase; P-30 is a 15kDa protein isolated from Pannon; it is an anti-tumor amphibian oocyte RNase found in Rana pipiens eggs and early embryos

Also Known As:

Networked: 105 relevant articles (8 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shogen, Kuslima: 15 articles (11/2011 - 01/2002)
2.	Raines, Ronald T: 12 articles (11/2011 - 03/2002)
3.	Darzynkiewicz, Zbigniew: 10 articles (07/2014 - 08/2002)
4.	Ardelt, Barbara: 9 articles (07/2014 - 08/2002)
5.	Lee, Intae: 6 articles (07/2008 - 01/2003)
6.	Shogen, K: 6 articles (06/2008 - 03/2000)
7.	Mikulski, S M: 6 articles (12/2002 - 03/2000)
8.	Arndt, Michaela A E: 5 articles (05/2015 - 06/2008)
9.	Krauss, Jürgen: 5 articles (05/2015 - 06/2008)
10.	Benito, Antoni: 5 articles (01/2013 - 03/2004)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2008 - "Ranpirnase has been shown to target malignant cells both in human cancer cell lines and in animal models, and has demonstrated efficacy in the treatment of several human cancers in clinical studies. " 03/01/2015 - "Onconase is currently used in clinical trials for cancer therapy; however, the precise mechanisms determining cytotoxicity in cancer cells have not yet been fully investigated. " 02/01/2015 - "Clinical trials employing single agent Ranpirnase in cancer patients have demonstrated significant clinical activity and surprisingly low immunogenicity. " 05/10/2012 - "In this study, a modular and multi-stage drug delivery system (DDS) that can break down organ (renal accumulation), cellular (cancer cell specific uptake) and sub-cellular (endosomal escape) level barriers encountered by Onconase during its long journey from injection site to the cytoplasm of cancer cell was designed. " 03/19/2004 - "Onconase (ONC) is currently in Phase III clinical trials as a cancer chemotherapeutic agent. "
2.	Lung Neoplasms (Lung Cancer) 09/01/2007 - "The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer." 04/01/1995 - "Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase(r) with other anticancer agents." 07/01/2008 - "Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer." 01/01/2007 - "Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice." 01/01/2007 - "Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice."
3.	Mesothelioma 01/01/2010 - "Most recently a phase III study of onconase in patients with mesothelioma was completed. " 01/01/2010 - "In this study, microarray analysis was used to compare gene expression profiles in untreated human malignant mesothelioma (MM) cell lines and cells exposed to 5 microg/ml Onconase for 24 h. " 12/01/2008 - "A large phase II trial showed that ranpirnase has disease-modifying activity against malignant mesothelioma. " 06/01/2008 - "Extensively studied Onconase is in advanced Phase IIIb clinical trials against malignant mesothelioma, while Amphinase is a novel enzyme in pre-clinical development. " 01/01/2007 - "Alfacell completed a phase III trial of single-agent ranpirnase in patients with unresectable malignant mesothelioma in April 1999. "
4.	Neuroblastoma 05/18/2007 - "The efficacy of Onconase on the growth of a panel of chemosensitive and chemoresistant neuroblastoma cell lines was investigated. " 05/18/2007 - "Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells." 04/14/1998 - "[Met-(-1)]rOnc(E1S) and [Met-(-1)]rOnc(E1Y) inhibited protein synthesis in intact SF539 neuroblastoma cells with IC50's very similar to that of onconase (IC50 3.5, 10, and 10 microg/mL after 1 day and 0.16, 0.35, and 2.5 microg/mL after 5 days for onconase, [Met-(-1)]rOnc(E1S), and [Met-(-1)]rOnc(E1Y), respectively). " 05/18/2007 - "Antitumour activity of Onconase against naïve and drug-resistant neuroblastoma xenografts was confirmed in animals." 05/18/2007 - "Onconase decreased cell viability of chemosensitive (IMR-32, UKF-NB-3) and chemoresistant neuroblastoma cell lines characterised by high expression of P-glycoprotein (P-gp) (UKF-NB-3(r)DOX(20)) or by high P-gp expression in combination with mutated p53 (UKF-NB-3(r)VCR(10), Be(2)-C), in a similar manner. "
5.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2001 - "This phase II trial tested ranpirnase (480 microg/m2/w) in 14 patients with refractory advanced renal cell cancer. " 01/01/2001 - "At this dose and schedule ranpirnase has minimal activity in metastatic renal cell cancer." 01/01/2005 - "Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. "

Related Drugs and Biologics

1.	Ribonucleases (Ribonuclease)
2.	RNA (Ribonucleic Acid)
3.	Phosphotransferases (Kinase)
4.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
5.	ranpirnase (Pannon)
6.	Pancreatic Ribonuclease (Ribonuclease A)
7.	Doxorubicin (Adriamycin)
8.	Tamoxifen
9.	Cytostatic Agents
10.	Proteasome Endopeptidase Complex (Proteasome)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Lasers (Laser)